Febrile Neutropenia and Immunotherapy Related Adverse Events

Febrile Neutropenia and Immunotherapy Related Adverse Events

Febrile Neutropenia

All patients presenting with fever following chemotherapy are at risk of neutropenic sepsis.

For management guidelines please refer to the EviQ website: Immediate Management of Neutropenic Fever https://www.eviq.org.au/clinical-resources/oncological-emergencies/123-immediate-management-of-neutropenic-fever

 

Immunotherapy Related Adverse Events (IRAES)

Immunotherapies used for cancer treatment are designed to elicit &/or amplify an immune response to help fight tumour growth and spread.

Immunotherapy can also cause the immune system to attack normal organs and tissue which can be associated with immune related adverse reactions that involve the lungs, intestines, liver, kidneys, hormone glands, and other organs, as well as infusion-related reactions.

Early diagnosis and appropriate management are essential to minimise these effects. For further information on IRAES visit https://www.eviq.org.au/clinical-resources/side-effect-and-toxicity-management/immunological/1993-management-of-immune-related-adverse-events